Experience with mixed infections of Plasmodium falciparum and vivax.
D000962:Antimalarials / Q000009:adverse effects; D002738:Chloroquine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008887:Military Medicine; D010963:Plasmodium falciparum; D010966:Plasmodium vivax; D011319:Primaquine / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D013444:Sulfisoxazole / Q000627:therapeutic use; D014481:United States; D014744:Vietnam
D000962:Antimalarials; D013444:Sulfisoxazole; D002738:Chloroquine; D003622:Dapsone; D011803:Quinine; D011319:Primaquine; D011739:Pyrimethamine